KR102220969B1 - N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염 - Google Patents

N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염 Download PDF

Info

Publication number
KR102220969B1
KR102220969B1 KR1020207003401A KR20207003401A KR102220969B1 KR 102220969 B1 KR102220969 B1 KR 102220969B1 KR 1020207003401 A KR1020207003401 A KR 1020207003401A KR 20207003401 A KR20207003401 A KR 20207003401A KR 102220969 B1 KR102220969 B1 KR 102220969B1
Authority
KR
South Korea
Prior art keywords
compound
salt
hemisulphate
cgrp
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003401A
Other languages
English (en)
Korean (ko)
Other versions
KR20200016993A (ko
Inventor
다니엘 리차드 로버츠
리차드 레이먼드 샤츠맨
첸코우 웨이
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102220969(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200016993A publication Critical patent/KR20200016993A/ko
Application granted granted Critical
Publication of KR102220969B1 publication Critical patent/KR102220969B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020207003401A 2012-02-27 2013-02-25 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염 Active KR102220969B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
US61/603,598 2012-02-27
PCT/US2013/027648 WO2013130402A1 (en) 2012-02-27 2013-02-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147023856A Division KR102076118B1 (ko) 2012-02-27 2013-02-25 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염

Publications (2)

Publication Number Publication Date
KR20200016993A KR20200016993A (ko) 2020-02-17
KR102220969B1 true KR102220969B1 (ko) 2021-02-25

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207003401A Active KR102220969B1 (ko) 2012-02-27 2013-02-25 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염
KR1020147023856A Active KR102076118B1 (ko) 2012-02-27 2013-02-25 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147023856A Active KR102076118B1 (ko) 2012-02-27 2013-02-25 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염

Country Status (26)

Country Link
US (1) US8759372B2 (https=)
EP (2) EP3254681B1 (https=)
JP (2) JP6208154B2 (https=)
KR (2) KR102220969B1 (https=)
CN (1) CN104136437B (https=)
AU (1) AU2013226361B2 (https=)
BR (1) BR112014021032B1 (https=)
CA (1) CA2865585C (https=)
CY (2) CY1119448T1 (https=)
DK (2) DK2820016T3 (https=)
EA (1) EA025358B1 (https=)
ES (2) ES2746031T3 (https=)
HK (1) HK1248111B (https=)
HR (2) HRP20171620T1 (https=)
HU (2) HUE047050T2 (https=)
IL (1) IL234272B (https=)
LT (2) LT3254681T (https=)
MX (1) MX352171B (https=)
NO (1) NO2935439T3 (https=)
PL (2) PL3254681T3 (https=)
PT (2) PT3254681T (https=)
RS (2) RS59295B1 (https=)
SG (1) SG11201404834XA (https=)
SI (2) SI2820016T1 (https=)
SM (1) SMT201700489T1 (https=)
WO (1) WO2013130402A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
HUE047050T2 (hu) * 2012-02-27 2020-04-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CA3035561A1 (en) * 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) * 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
MX2021008191A (es) * 2019-01-20 2021-08-11 Biohaven Pharm Holding Co Ltd Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
US12521389B2 (en) * 2019-06-14 2026-01-13 The Regents Of The University Of California Therapeutic approach to lung disease
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor
WO2026074002A1 (en) 2024-10-02 2026-04-09 Krka, D.D., Novo Mesto Crystalline salts of rimegepant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046997A1 (en) 2009-10-14 2011-04-21 Bristol-Myers Squibb Company Cgrp receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7855294B2 (en) 2004-03-05 2010-12-21 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
DE602005027230D1 (de) 2004-10-22 2011-05-12 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
JP2009533438A (ja) 2006-04-10 2009-09-17 メルク エンド カムパニー インコーポレーテッド ピリジン複素環ｃｇｒｐアンタゴニスト中間体の製造方法
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
HUE047050T2 (hu) * 2012-02-27 2020-04-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046997A1 (en) 2009-10-14 2011-04-21 Bristol-Myers Squibb Company Cgrp receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERL. Helvetica Chimica Acta, pp.162-173, 2002

Also Published As

Publication number Publication date
JP2015511581A (ja) 2015-04-20
CN104136437A (zh) 2014-11-05
ES2746031T3 (es) 2020-03-04
ES2642737T3 (es) 2017-11-17
RS56556B1 (sr) 2018-02-28
CN104136437B (zh) 2016-05-11
BR112014021032B1 (pt) 2022-09-27
JP6476253B2 (ja) 2019-02-27
SI3254681T1 (sl) 2019-10-30
JP6208154B2 (ja) 2017-10-04
DK3254681T3 (da) 2019-09-30
KR20200016993A (ko) 2020-02-17
DK2820016T3 (da) 2017-11-13
AU2013226361A1 (en) 2014-10-16
EA201491585A1 (ru) 2015-01-30
IL234272B (en) 2018-10-31
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
SI2820016T1 (sl) 2017-11-30
CA2865585C (en) 2019-12-10
PT3254681T (pt) 2019-10-01
HK1248111B (en) 2020-04-17
EA025358B1 (ru) 2016-12-30
LT3254681T (lt) 2019-09-25
HRP20171620T1 (hr) 2017-12-01
EP3254681A1 (en) 2017-12-13
CY1119448T1 (el) 2018-03-07
LT2820016T (lt) 2017-10-25
KR102076118B1 (ko) 2020-02-11
PL3254681T3 (pl) 2019-12-31
JP2017226693A (ja) 2017-12-28
HUE034936T2 (hu) 2018-03-28
BR112014021032A2 (https=) 2017-06-20
KR20140130140A (ko) 2014-11-07
SG11201404834XA (en) 2014-09-26
SMT201700489T1 (it) 2017-11-15
WO2013130402A1 (en) 2013-09-06
US8759372B2 (en) 2014-06-24
CY1122121T1 (el) 2020-11-25
EP2820016B1 (en) 2017-08-02
HRP20191655T1 (hr) 2019-12-13
PT2820016T (pt) 2017-10-18
CA2865585A1 (en) 2013-09-06
AU2013226361B2 (en) 2017-09-21
EP2820016A1 (en) 2015-01-07
US20130225636A1 (en) 2013-08-29
NO2935439T3 (https=) 2018-03-31
EP3254681B1 (en) 2019-06-19
MX352171B (es) 2017-11-13
HUE047050T2 (hu) 2020-04-28
RS59295B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
KR102220969B1 (ko) N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염
HK1248111A1 (en) N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
JP7833597B2 (ja) Ｃｄｋ２阻害剤としての二環式アミン
JP6587116B2 (ja) キナゾリン化合物
JP6777652B2 (ja) 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物
KR20210143263A (ko) 이미다졸로닐퀴놀린 화합물 및 그의 치료적 용도
US9845314B2 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
KR20130116302A (ko) 이미다조 [４,５-ｃ]퀴놀린-2-온 화합물 및 ｐｉ３ 키나제/ｍｔｏｒ 이중 억제제로서의 그의 용도
CN110028509B (zh) 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
CN111094273B (zh) 催产素受体抑制剂的晶型及其制备方法
CN111094272B (zh) 一种otr抑制剂的可药用盐、晶型及制备方法
TW202340167A (zh) 含硫異吲哚啉類衍生物的晶型
CN119546607A (zh) Lrrk2抑制剂

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200205

Application number text: 1020147023856

Filing date: 20140826

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200305

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200317

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201019

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201019

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200625

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200305

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20201126

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20201119

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201019

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200625

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200305

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 5

End annual number: 5

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20250624

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.